Last updated: August 1, 2026
Unoprostone isopropyl is a topical prostaglandin analog formerly marketed in the United States as Rescula for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Its commercial position has largely ended: the U.S. product was discontinued for business reasons, no active late-stage development program is evident, and the drug has been displaced by latanoprost, bimatoprost, travoprost, tafluprost and newer glaucoma therapies. Near-term global revenue potential is limited unless a company reintroduces the product in a price-sensitive or underserved market.
What is unoprostone isopropyl and how does it work?
Unoprostone isopropyl is an ophthalmic prostaglandin analog supplied as a 0.15% ophthalmic solution. It lowers intraocular pressure through increased aqueous humor outflow, with activity involving the trabecular meshwork and uveoscleral pathways. The drug was developed for glaucoma and ocular hypertension rather than retinal disease or systemic hypertension.
| Attribute |
Unoprostone isopropyl |
| Brand |
Rescula |
| Dosage form |
Ophthalmic solution |
| Strength |
0.15% |
| Therapeutic area |
Glaucoma and ocular hypertension |
| Drug class |
Prostaglandin analog |
| U.S. sponsor at approval |
Novartis Pharmaceuticals Corporation |
| U.S. indication |
Reduction of elevated intraocular pressure |
| Administration |
Topical ophthalmic |
| U.S. regulatory status |
Approved, later discontinued |
| Principal commercial competitors |
Xalatan, Lumigan, Travatan Z, Zioptan, Rocklatan, Vyzulta |
The U.S. label specified twice-daily administration. That dosing frequency was commercially disadvantageous compared with once-daily products that became standard in the prostaglandin market.[1]
What is the FDA status of unoprostone isopropyl?
The FDA approved Rescula ophthalmic solution in 2000 for reducing elevated intraocular pressure in open-angle glaucoma and ocular hypertension.[1] The product was subsequently discontinued in the United States. The discontinuation was classified as a commercial decision rather than a withdrawal for safety or efficacy concerns.
The distinction matters for regulatory strategy. A commercially discontinued product may be eligible for future development or reintroduction if a sponsor can address manufacturing, supply, labeling and commercial positioning. Discontinuation alone does not establish that the active ingredient is unsafe or clinically ineffective.
What is the Orange Book status of Rescula?
Rescula is no longer a meaningful U.S. Orange Book exclusivity asset. Any original listed patents and regulatory exclusivities have expired or ceased to provide a commercially relevant barrier to generic entry. The product’s practical U.S. barrier is therefore market economics, not remaining branded exclusivity.
A sponsor seeking reentry would face:
- An established generic-equivalent pathway for the ophthalmic solution.
- Bioequivalence and pharmaceutical equivalence requirements.
- Manufacturing validation for a sterile ophthalmic product.
- The need to demonstrate adequate stability, container closure integrity and preservative performance.
- Commercial competition from once-daily prostaglandin products.
- Limited physician incentive to switch patients from established therapies.
Are there active clinical trials for unoprostone isopropyl?
No active late-stage clinical development program is evident in the major public trial registries and regulatory record through 2024. The clinical evidence base is primarily historical, consisting of trials conducted before and around the original U.S. approval.
The development program evaluated intraocular-pressure reduction in open-angle glaucoma and ocular hypertension. Historical studies established pharmacodynamic activity, but the available evidence did not produce a durable commercial advantage over competing prostaglandin analogs.
| Development question |
Current assessment |
| Active Phase 3 program |
None identified |
| Active pivotal U.S. program |
None identified |
| New indication development |
None identified |
| Biosimilar development |
Not applicable |
| U.S. reapproval program |
None identified |
| Main evidence base |
Historical glaucoma and ocular-hypertension trials |
What clinical limitations affected adoption?
The principal commercial limitations were dosing frequency and competitive positioning. Unoprostone isopropyl was generally administered twice daily, while latanoprost and several competing products were administered once daily. Prostaglandin analogs also compete on preservative tolerability, ocular hyperemia, iris pigmentation, eyelash growth, dosing convenience and reimbursement.
Unoprostone’s clinical profile did not create a sufficiently differentiated position in the first-line glaucoma market. It remained a niche option rather than a market-leading prostaglandin.
How does unoprostone isopropyl compare with competing glaucoma drugs?
Unoprostone competes in a mature class dominated by generic and branded prostaglandin analogs. The most important comparison is dosing convenience and cost.
| Drug |
Typical dosing |
Market position |
Competitive assessment |
| Unoprostone isopropyl |
Twice daily |
Discontinued or limited-market product |
Weak commercial position |
| Latanoprost |
Once daily |
Generic market leader |
Strong cost and prescribing position |
| Bimatoprost |
Once daily |
Branded and generic use |
Strong efficacy perception |
| Travoprost |
Once daily |
Branded and generic use |
Established alternative |
| Tafluprost |
Once daily |
Preservative-free niche |
Differentiated tolerability profile |
| Netarsudil/latanoprost |
Once daily |
Combination therapy |
Higher-value branded competition |
| Latanoprostene bunod |
Once daily |
Newer branded therapy |
Nitric-oxide pathway differentiation |
Unoprostone could have a limited role where physicians value its tolerability profile, where competitors are unavailable, or where a local sponsor can offer a low-cost product. Those opportunities do not support a large global forecast.
What patents protect unoprostone isopropyl?
The original U.S. patent estate was associated with the active compound, ophthalmic formulations and glaucoma treatment methods. Those rights were filed and prosecuted decades before the product’s commercial decline. The relevant patent terms have expired for commercial purposes.
| IP category |
Current commercial relevance |
| Active-compound patents |
Expired |
| Ophthalmic formulation patents |
Expired or no longer commercially blocking |
| Method-of-use patents |
Expired |
| Manufacturing patents |
No identified active barrier of material market significance |
| U.S. Orange Book protection |
No meaningful remaining exclusivity |
| Biosimilar protection |
Not relevant because this is a small molecule |
A new sponsor could still pursue patents covering a genuinely novel formulation, preservative system, delivery device or manufacturing process. Such patents would not restore exclusivity to the original unoprostone isopropyl product. They would protect only the newly claimed technology and would need to overcome obviousness and enablement risks in a mature ophthalmic field.
What generic entry risks exist for unoprostone isopropyl?
Generic entry risk is high because the original branded product has no durable exclusivity advantage. A generic sponsor would likely pursue an abbreviated regulatory pathway if the reference product and applicable regulatory standards remain available.
The principal barriers are technical rather than legal:
- Sterile ophthalmic manufacturing.
- Demonstration of equivalent strength and dosage form.
- Preservative and microbiological performance.
- Stability across the labeled shelf life.
- Reliable supply of active pharmaceutical ingredient.
- Limited commercial return from a small and mature market.
The low expected price of a generic product may deter entry despite the absence of patent protection. Ophthalmic products require specialized manufacturing and distribution, while established generic competitors already have relationships with payers and wholesalers.
What is the market outlook for unoprostone isopropyl?
The global glaucoma market remains substantial because aging populations increase the prevalence of ocular hypertension and glaucoma. That market growth does not translate into equivalent growth for unoprostone. Most incremental value is captured by generic latanoprost and differentiated branded products, including fixed-dose combinations and preservative-free formulations.
Base-case projection
The base case is continued commercial decline or negligible revenue in the United States, with limited regional sales where unoprostone remains registered or available through local distributors. No credible basis exists for forecasting a return to blockbuster status.
| Period |
Base-case outlook |
| 2024-2026 |
No meaningful U.S. branded recovery; limited regional availability |
| 2027-2029 |
Continued erosion as generic prostaglandins dominate |
| 2030 onward |
Niche or discontinued status unless a new formulation is introduced |
Upside scenario
An upside case would require a new sponsor to establish a differentiated product, such as:
- A preservative-free formulation.
- A once-daily formulation with comparable exposure.
- A novel multidose container.
- A combination product.
- A market-specific low-cost product for regions with limited access to newer therapies.
Even under that scenario, the product would compete against established once-daily prostaglandins and generic fixed-dose combinations. A reformulation could support a focused specialty launch, but it would not automatically create broad market demand.
Downside scenario
The downside case is complete market withdrawal. This would occur if active registrations lapse, API supply becomes uneconomic, or generic manufacturers conclude that expected volume does not justify sterile manufacturing investment.
Which companies are challenging or competing with unoprostone isopropyl?
No major current litigation or Paragraph IV campaign directed specifically at unoprostone isopropyl is evident in the public record. The competitive threat comes from established glaucoma products rather than active patent challenges.
Key competitive companies and products have included:
- Viatris and other generic manufacturers selling latanoprost.
- AbbVie, through glaucoma products including Lumigan and related ophthalmic assets.
- Novartis, historically associated with Rescula and other ophthalmic products.
- Alcon, associated with Travatan Z and broader ophthalmic products.
- Bausch + Lomb, with glaucoma products and generic ophthalmic capabilities.
- Santen, with ophthalmic and glaucoma products in selected markets.
What patent litigation and settlement agreements affect unoprostone isopropyl?
No material current U.S. patent litigation or settlement agreement appears to control market entry for unoprostone isopropyl. The relevant patent disputes were historical and linked to the original development and commercialization period.
The absence of current litigation does not mean the product is commercially attractive. It means that market access is mainly constrained by demand, manufacturing economics, regulatory maintenance and competition.
What manufacturing and licensing barriers affect the product?
Unoprostone isopropyl requires sterile ophthalmic production and quality control. The manufacturing process must control particulate matter, microbial contamination, preservative concentration, fill volume and container performance. Those requirements can make small-volume products uneconomic.
A licensing transaction would be more likely to involve regional rights, manufacturing rights or a portfolio transfer than a high-value global acquisition. Potential transaction value would depend on:
- Active registrations in target countries.
- Current supply agreements.
- API availability.
- Remaining trademarks.
- Product stability data.
- Historical safety and efficacy files.
- Access to a sterile ophthalmic manufacturing network.
- Reimbursement status.
There is no evident basis for assigning a significant global licensing premium to the legacy product alone.
What is the revenue exposure and commercial opportunity?
Revenue exposure for the original branded product is low. The glaucoma therapeutic area remains commercially important, but unoprostone captures little of that value because it lacks current U.S. exclusivity, has a twice-daily regimen and faces generic alternatives.
A reasonable commercial classification is:
| Metric |
Assessment |
| Current U.S. branded revenue potential |
Minimal |
| Global legacy-product potential |
Low and region-dependent |
| Reimbursement leverage |
Weak |
| Probability of blockbuster reentry |
Very low |
| Generic manufacturing opportunity |
Selective |
| Reformulation opportunity |
Moderate but technically and commercially uncertain |
| Strategic value |
Portfolio or regional niche rather than core growth asset |
Key Takeaways
- Unoprostone isopropyl is a legacy prostaglandin analog formerly sold as Rescula.
- The FDA-approved product was discontinued in the United States for commercial reasons.
- No active late-stage clinical development program is evident through 2024.
- Original compound, formulation and method-of-use exclusivities no longer provide a meaningful commercial barrier.
- There is no material current Paragraph IV or patent-litigation risk identified.
- The main competitive disadvantages are twice-daily dosing, limited differentiation and competition from generic once-daily prostaglandins.
- A generic launch is technically possible but may be unattractive because of sterile ophthalmic manufacturing costs and limited demand.
- The strongest redevelopment opportunity would involve a preservative-free, once-daily, combination or delivery-system reformulation.
- The base-case forecast is negligible U.S. revenue and limited regional sales, not a broad market recovery.
FAQs About Unoprostone Isopropyl
Is unoprostone isopropyl still available in the United States?
The branded U.S. product Rescula was discontinued. Availability through lawful U.S. commercial channels is limited and does not represent an active branded market.
Is unoprostone isopropyl a prostaglandin analog?
Yes. It is an ophthalmic prostaglandin analog used to reduce elevated intraocular pressure in glaucoma and ocular hypertension.
Can a generic company launch unoprostone isopropyl?
A generic company could evaluate an abbreviated regulatory pathway, subject to reference-product availability, FDA requirements and sterile ophthalmic manufacturing capability. Commercial demand is the primary constraint.
Does unoprostone isopropyl have biosimilar risk?
No. Unoprostone isopropyl is a small-molecule drug, so it faces generic-drug competition rather than biosimilar competition.
Could a new formulation revive unoprostone isopropyl?
A new formulation could create a limited specialty opportunity if it improves dosing frequency, preservative tolerability, delivery or combination therapy. Any protection would come from new formulation or device patents, not from the expired legacy product estate.
References
-
U.S. Food and Drug Administration. (2000). Rescula (unoprostone isopropyl ophthalmic solution) prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Rescula, NDA 020785. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
National Library of Medicine. (n.d.). Unoprostone isopropyl. PubChem. https://pubchem.ncbi.nlm.nih.gov/
-
National Library of Medicine. (n.d.). ClinicalTrials.gov database. https://clinicaltrials.gov/
-
World Health Organization. (2023). World report on vision and glaucoma-related eye health data. https://www.who.int/initiatives/avoidable-blindness-vesm refractive-error-and-glaucoma-related-resources
